SecondConsecutive Nomination Recognizes SEED’s Progress in Rational Molecular Glue Developmentand Targeted Protein Degradation

RecognitionFollows First-in-Human Proof of Mechanism for Lead RBM39 Degrader ST-01156 inan Ongoing Phase 1 Study

KING OF PRUSSIA, PA, August17, 2026 — SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology companypioneering rationally designed molecular glue degraders, today announced thatit has been nominated for the 2026 Prix Galien USA “Best Start-Up” Award forthe second consecutive year (Prix Galien USA 2026 Press Release Link).

The Galien Foundation fosters,recognizes, and rewards excellence in scientific innovation to improve humanhealth. The Prix Galien Awards recognize innovations that address significantunmet medical needs and demonstrate scientific rigor, clinical relevance, andthe potential to improve human health. SEED was also nominated for the 2025Prix Galien USA “Best Start-Up” Award.

Since its nomination in 2025, SEED hasadvanced ST-01156, an oral, brain-penetrant RBM39 molecular glue degrader, intoan ongoing first-in-human Phase 1 study in patients with advanced solid tumors.Dose escalation has progressed to the third cohort, with encouraging safety andpharmacokinetic findings to date, no dose-limiting toxicities observed, and confirmedRBM39 degradation in patient blood cells, providing first-in-human proof ofmechanism. Powered by its proprietary RITE3™ platform, SEED is pursuing amechanism-driven development strategy for ST-01156 while advancing a broaderpipeline across oncology, neurodegeneration, and immunology, including a whollyowned Tau degrader and a second oncology program.

“The Prix Galien USA nominationfor a second consecutive year reflects SEED’s progress in translating itsmolecular glue platform into clinical development,” said Lan Huang, Ph.D.,Co-Founder, Chairman, and Chief Executive Officer of SEED Therapeutics. “Overthe past year, we advanced ST-01156 from IND clearance to an active Phase 1study and established early clinical proof of mechanism through RBM39degradation in patients. This distinction reflects the strength of our science,the execution of our team, and our continued commitment to developingrationally designed therapies for diseases driven by historically undruggableproteins.”

The 2026 Prix GalienUSA Awards ceremony will be held on October 29, 2026, at the AmericanMuseum of Natural History in New York City.

About SEED Therapeutics

SEED Therapeutics is a clinical-stagebiotechnology company developing rationally designed molecular glue degradersto treat diseases driven by proteins previously considered undruggable. Itsproprietary RITE3™ platform enables selective targeted protein degradation witha defined therapeutic window, supporting a pipeline of six molecular glueprograms across oncology, neurodegeneration, and immunology.

SEED was co-founded by four preeminent scientists:

•  Nobel Laureate Prof. AvramHershko, co-discoverer of theubiquitin-proteasome system, the cellular machinery that SEED’s molecular gluedegraders harness to eliminate disease-causing proteins.

•  Dr. Lan Huang, pioneering structural biochemist who determinedthe first high-resolution structure of an E3 ligase substrate-binding domain,providing foundational insight into how targeted protein degradation can berationally designed.

•  Prof. Ning Zheng (University of Washington, HHMI Investigator),structural biologist and pioneer of RING finger E3 ligase mechanisms, and thescientist who coined the term “molecular glue” to describe small molecules thatredirect E3 ligases to degrade neo-substrates.

•  Prof. Michele Pagano (NYU Grossman School of Medicine, HHMIInvestigator), one of the world’s foremost authorities on ubiquitin-mediatedproteolysis and its role in cell cycle control and cancer, whose work hasdefined how E3 ligase dysregulation drives tumor development.

Additional information is available at www.seedtherapeutics.com.

Forward-LookingStatements

This press release contains forward-looking statements regarding SEEDTherapeutics, including statements about the design and progress of itsclinical and preclinical programs. Actual results may differ materially due tovarious risks, including those inherent to drug development. SEED undertakes noobligation to update these statements except as required by law.

Media and Investor Contacts

Investor Relations: IR@seedtherapeutics.com

Media Relations: PR@seedtherapeutics.com

‍